Purdue Pharma’s bankruptcy deal fair to creditors


Seeking justice: Family and friends who have lost loved ones to OxyContin and opioid overdoses leave pill bottles in protest outside the headquarters of Purdue Pharma in Stamford. — AP

NEW YORK: During the final day of argument in Purdue Pharma’s bankruptcy trial, lawyers for the OxyContin maker said its proposed US$10bil (RM42bil) settlement of opioid claims is by far the best deal for creditors.

Seeking to convince US bankruptcy judge Robert Drain that Purdue’s proposal is better than a liquidation of the business and free-for-all litigation stampede against itself and its owners, Marshall Huebner of Davis Polk & Wardwell, said the plan would deliver at least US$5.5bil (RM23.1bil) of cash to creditors.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Purdue Pharma , deal , bankruptcy , creditors ,

   

Next In Business News

HeiTech Padu proposes private placement to raise RM22.98mil for working capital
Ringgit stages technical rebound to snap 3-day losing streak against US$
Bursa Malaysia snaps 4-day losing streak to end higher
Oil dips as demand worries outweigh Middle East supply risks
IGB REIT cautious on retail sales growth
Are we destined for war?
IMF revises Malaysia's 2024 GDP higher to 4.4%
Higher stakes for stakeholders
Balancing act for effective governance
Bank Islam manages to mitigate impact of static OPR in 2023

Others Also Read